Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indinavir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.99 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.99 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.99 |
| ▸ | TACR2 | P21452 | 1/20 | 0.99 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.99 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.99 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.99 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indinavir Anhydrous SCHEMBL17787450 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL7752012 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL8033526 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL13575769 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL6766271 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL2671734 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL14287519 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL20399698 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL21683359 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL21578565 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889153-B2 | Combination of immunomodulator and anti-pathogenic agent | NUNES ISEU DA SILVA (BR) | 2014-11-18 | — | — | US | disclosed |
| EP-2259799-B1 | COMBINATION OF IMMUNOMODULATOR AND ANTI-PATHOGENIC AGENT | NUNES ISEU DA SILVA (BR) | 2014-03-12 | — | — | EP | disclosed |
| US-20110028385-A1 | Combination of Immunomodulator and Anti-Pathogenic Agent | NUNES ISEU DA SILVA | 2011-02-03 | — | — | US | disclosed |
| WO-2009114895-A1 | DIAGNOSTIC, THERAPEUTIC AND PROPHYLACTIC METHOD AND SCREENING METHOD | THE UNIVERSITY OF SYDNEY (AU) | 2009-09-24 | — | — | WO | disclosed |
| US-7572928-B2 | Fluorination process | ISIS INNOVATION LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-20070142632-A1 | Fluorination process | ISIS INNOVATION LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070009593-A1 | Methods of treating cancer | Indianan University Advanced Research | 2007-01-11 | — | — | US | disclosed |
| US-20070009593-A1 | Methods of treating cancer | Indianan University Advanced Research | 2007-01-11 | — | — | US | disclosed |
| WO-2004010937-A2 | METHOD OF TREATING CANCER | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE AT INDIANA UNIVERSITY (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070009593-A1 | Methods of treating cancer | CAPN2, CAPN9, CAPN1 | CYP3A4 2906/4885ABCC3 2498/4885ABCB11 3462/4885 |
| US-20070142632-A1 | Fluorination process | CYP2F1, SF3A2, SF3B2 | CYP3A4 67/4885ABCC3 1450/4885ABCB11 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.